ETSI releases first O-RAN specification
15.9.2022 17:00:00 EEST | Business Wire | Press release
ETSI and O-RAN are pleased to announce that ETSI has adopted the first O-RAN specification as ETSI TS 103 859, namely ‘O-RAN Fronthaul Control, User and Synchronization Plane Specification v7.02’. The document focuses on Open Fronthaul, one of interfaces in the O-RAN Architecture for open and intelligent Radio Access Networks. It specifies the control plane, user plane and synchronization plane protocols used over the fronthaul interface linking the O-DU (O-RAN Distributed Unit) and the O-RU (O-RAN Radio Unit) for the lower layer functional splits. The scope of TS 103 859 includes both LTE and NR (5G).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220915005642/en/
“Recognition of O-RAN specifications by ETSI is another major step in enabling broad adoption of Open RAN,” said Claire Chauvin, O-RAN Board member and Strategy Architecture and Standardization Director at Orange. “Having the O-RAN specification available as an ETSI specification adds further endorsement desired by commercial and public sector entities in a range of countries.”
“The O-RAN specification has been approved as an ETSI specification after a thorough review and requested revisions by our experts,” said Dominique Everaere, Chair of the ETSI Mobile Standards Group Technical Committee. “When specifications go through the ETSI PAS process, they need to comply with the ETSI rules, and the ETSI committee in charge of these specifications works with the organization to ensure they align with existing procedures for approval as ETSI standards.”
The ETSI Publicly Available Specification (PAS) process enables an ETSI partner to submit one or more of its PAS for adoption by ETSI. It can then become an ETSI Technical Specification (TS) or ETSI Technical Report (TR). The organization asking for this process must be a legal entity, have an IPR policy compatible with ETSI’s or have exceptionally accepted to apply ETSI’s IPR policy, and have signed a Cooperation Agreement.
O-RAN is preparing to submit more of its specifications to the ETSI PAS process to recognize additional parts of the O-RAN Architecture as ETSI specifications.
About ETSI
ETSI provides members with an open and inclusive environment to support the development, ratification and testing of globally applicable standards for ICT systems and services across all sectors of industry and society. We are a non-profit body, with more than 900 member organizations worldwide, drawn from 64 countries and five continents. The members comprise a diversified pool of large and small private companies, research entities, academia, government, and public organizations. ETSI is officially recognized by the EU as a European Standardization Organization (ESO). For more information, please visit us at https://www.etsi.org/.
About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of more than 320 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN specifications enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks at the same time improve the efficiency of RAN deployments as well as operations by the mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For more information, please visit www.o-ran.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005642/en/
Contact information
ETSI Press contact:
Claire Boyer
Tel.: +33 (0)6 87 60 84 40
Email: claire.boyer@etsi.org
O-RAN ALLIANCE PR Contact:
Zbynek Dalecky
pr@o-ran.org
O-RAN ALLIANCE e.V.
Buschkauler Weg 27
53347 Alfter/Germany
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on CASGEVY ® , Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions11.6.2026 09:01:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, from pivotal studies in children ages 5–11, show that the efficacy and safety outcomes in this age group are consistent with the transformative profile established in adult and adolescent patients. These data were presented at the European Hematology Association (EHA) Congress and simultaneously published in the New England Journal of Medicine (NEJM). “The data presented at EHA and published in NEJM underscore the consistent, durable and transformative benefits CASGEVY can provide to people living with sickle cell disease or transfusion-dependent beta thalassemia from early in life,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Off
PUMA Brings NITRO™ to Football With the PUMA NITRO Lab in Los Angeles11.6.2026 09:00:00 EEST | Press release
Global sports brand PUMA today opened the PUMA NITRO™ Lab in Los Angeles, the latest chapter of its innovation platform, and company’s most significant yet, marking the global reveal of the Ultra Nitro 7 and NITRO™'s arrival in football for the first time on a football boot. Previous editions of the NITRO™ Lab in Paris, Tokyo, and London explored the future of running performance and cemented NITRO™ as the defining technology in elite running with Fast-R3. Now, with the world’s attention turning to football, Los Angeles is where that journey takes its next step, introducing the same innovation DNA that reshaped the track to the pitch, when it matters most. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610728823/en/ Global sports brand PUMA today opened the PUMA NITRO™ Lab in Los Angeles, the latest chapter of its innovation platform, and company’s most significant yet, marking the global reveal of the Ultra Nitro 7 and N
AHS Properties Acquires Shangri-La Hotel for AED 1.1 Billion in Landmark Sheikh Zayed Road Transaction11.6.2026 09:00:00 EEST | Press release
AHS Properties today announced the acquisition of Shangri-La Hotel for AED 1.1 billion, one of the largest single-asset real estate transactions recorded in recent history. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605096792/en/ Shangri-La Hotel Exterior, Sheikh Zayed Road. (Photo: AETOSWire) Acquired from Mismak Asset Management, the transaction cements one of the most concentrated private-sector bets on Sheikh Zayed Road's next decade. The Shangri-La Hotel is a 43-floor, 200-metre tower on Sheikh Zayed Road, and was one of the first five-star hotels to open on the corridor when it was completed in 2003. The acquisition adds an iconic anchor asset to a portfolio that already includes AHS Tower, a recently sold-out Grade-A commercial development on Sheikh Zayed Road, and AHS City, the developer’s flagship master-planned, mixed-use community on the corridor with a forecast gross development value of AED 25 billion. To
Curatis Increases Revenue Growth Guidance for 202611.6.2026 08:00:00 EEST | Press release
Curatis Holding AG (SIX: CURN) increases its revenue growth guidance for the financial year 2026: the company is forecasting a revenue growth of approximately 40% in 2026, in contrast to the previous outlook of over 25%. Based on preliminary figures for the first five months of 2026, Curatis expects a significantly higher than anticipated revenue growth for 2026. This growth is driven by products that Curatis has marketed for some time, as well as by products added to its portfolio in 2025 and 2026. Under the new guidance, Curatis projects revenues of approximately CHF 15m in 2026, up from CHF 10.8m in 2025. Curatis will publish detailed financial figures for the first six months of 2026 in the half-year report on 21 September 2026. About Curatis Curatis Holding AG is a publicly listed company (CURN.SW) focused on the late stage development and commercialization of drugs for rare diseases and specialty care. Curatis has a sales portfolio of more than 40 products and a pipeline of orpha
Galderma Unveils New Global Survey Data Exploring the Evolving Expectations and Experiences of Patients and Healthcare Professionals With Anti-wrinkle Treatments11.6.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) has released findings from a landmark global survey conducted across the United States (U.S.), Brazil, the United Kingdom (UK), and China – the largest of its kind – exploring the evolving expectations and experiences of patients and HCPs with anti-wrinkle aesthetic treatments. As the dermatology category leader, this survey demonstrates Galderma’s commitment to advancing progress in this market, through robust clinical research, product performance, and practitioner support. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610228460/en/ Anti-wrinkle treatments are among the most established procedures in aesthetic medicine and currently represent the most commonly performed nonsurgical cosmetic treatment worldwide.2 The market is set to expand further, with 85% of surveyed patients globally indicating they plan to maintain or increase their use in the future, including 97% in China and 87% in the UK.2
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
